Discovers True Human monoclonal antibodies. Develops True Human monoclonal antibodies for treating various diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $125.6M in the vault; even if every debt were paid off, $125.6M would remain.
Over the last 12 months, company executives reported 6 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $45.5M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 17/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 34/100.
On our five-subject report card, XBIT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: XBIT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.